Jefferies

Company

Last mentioned: Mar 17, 2026

Timeline

  1. Target Completion

    Expected completion of the two-year workforce reduction and AI integration plan.

  2. Redemption Crisis

    Blackstone and Blue Owl Capital report redemption surges amid higher interest rates.

  3. Redemption Crisis

    Reports emerge of Blackstone and Blue Owl Capital struggling to meet investor redemption requests.

  4. DB Annual Disclosure

    Deutsche Bank officially reveals private credit risks and NBFI interconnectedness in its annual report.

  5. Annual Report Disclosure

    Deutsche Bank signals indirect credit risks from NBFIs and shadow banking weaknesses.

  6. AI Revamp Announcement

    CEO Zubin Appoo announces 2,000 job cuts and a shift away from manual coding.

  7. AI Pivot & Layoffs

    CEO Zubin Appoo announces 2,000 job cuts and H1 profit beat.

  8. Jefferies Analyst Note

    Jefferies issues high-conviction 65-75% probability for best-in-class efficacy.

  9. SaaS-pocalypse Coined

    Jefferies analysts signal a major downturn in SaaS valuations within private markets.

  10. Market Sentiment Shift

    Jefferies coins 'SaaS-pocalypse' as retail sentiment in private markets turns negative.

  11. Anticipated Readout

    Expected top-line data from the Phase III DT120 trial.

  12. Annual Report Period

    Deutsche Bank records $30B in private credit exposure and $18.1B in tech loans.

  13. Portfolio Growth

    Deutsche Bank builds $30B private credit exposure and $18.1B tech loan portfolio.

  14. Phase III Initiation

    Global Phase III trial for DT120 begins enrollment.

  15. E2open Acquisition

    WiseTech completes the $2.1 billion acquisition of U.S. cloud firm E2open.

  16. Phase II Success

    Definium publishes robust Phase II data for DT120.

  17. Record High & Scandal

    WiseTech shares hit record highs before a 70% drop following allegations against founder Richard White.

  18. Stock Collapse

    Shares drop 70% following allegations against founder Richard White.

  19. E2open Acquisition

    WiseTech acquires U.S. cloud firm E2open for $2.1 billion.

Stories mentioning Jefferies 7

market-trends Bearish

Deutsche Bank's $30B Private Credit Signal Sparks 'SaaS-pocalypse' Fears

Deutsche Bank has disclosed a $30 billion exposure to the private credit market, warning of systemic risks as interest rates and redemption pressures mount. The disclosure highlights a growing 'SaaS-pocalypse' sentiment, with $18.1 billion of the bank's tech exposure potentially vulnerable to shifting private market liquidity.

3 sources
regulation Bearish

Deutsche Bank Discloses $30B Private Credit Exposure Amid Systemic Risk Fears

Deutsche Bank has revealed a $30 billion exposure to the private credit market, warning that indirect risks from non-bank financial institutions could trigger significant credit losses. The disclosure comes as major asset managers like Blackstone and Blue Owl face a surge in redemptions, signaling a potential 'SaaS-pocalypse' for tech-heavy portfolios.

3 sources
markets Bearish

WiseTech Global to Cut 2,000 Jobs in AI-Driven Engineering Pivot

Australian logistics software giant WiseTech Global is slashing 29% of its workforce as it transitions from manual coding to AI-orchestrated development. The move follows a period of significant stock volatility and aims to integrate the recently acquired E2open while boosting operational efficiency.

2 sources
hr-tech Bearish

WiseTech Global to Cut 2,000 Jobs in AI-Driven Software Engineering Pivot

Australian logistics software leader WiseTech Global has announced a reduction of 2,000 roles, representing 29% of its workforce, as it transitions to AI-led software development. The two-year restructuring plan marks a fundamental shift away from manual coding toward automated engineering and operational efficiency.

2 sources
clinical-trial Bullish

Jefferies Bullish on Definium's DT120: 75% Odds for Best-in-Class Efficacy

Jefferies analysts have issued a high-conviction outlook on Definium Therapeutics' lead candidate, DT120, assigning a 65-75% probability that the drug will demonstrate best-in-class efficacy in its ongoing Phase III trials. This projection positions the company as a potential disruptor in its therapeutic category, significantly raising market expectations ahead of upcoming data readouts.

2 sources